Dear ladies and gentlemen, welcome to the Merck Investor and Analyst Conference Call on the Fourth Quarter 2024. As a reminder, all participants will be in a listen-only mode. I am now handing ...

EBITDA Pre Growth (Q4 2024): 20% organically. Proposed Dividend: EUR2.20 per share. Full Year 2024 Net Sales: EUR21.16 billion. Full Year 2024 EBITDA Pre: EUR6.07 billion. Full Year 2024 EPS Pre ...

Merck & Company Inc. (MRK) reported its financial results for the full year 2024, showing a slight increase in net sales and a notable improvement in operating cash flow. The company’s stock ...

Merck's stock trades at a low valuation as investors worry about Keytruda's looming patent cliff. The company is looking to a new, subcutaneous formulation, which could help sales remain strong.

While the pandemic has been the focus of R&D attention for much of 2020, that is slowly beginning to shift towards other projects in the big pharma pipeline. pharmaphorum’s news editor, Richard ...

GSK has reported pre-tax profit in the fourth quarter of £1.75 billion, which is up from £1.7 billion in the same period last year. Q4 turnover was down from last year’s total of £7 billion ...

Merck & Company Inc. (MRK) reported its financial results for the full year 2024, showing a slight increase in net sales and a notable improvement in operating cash flow. The company’s stock ...

EBITDA Pre Growth (Q4 2024): 20% organically. Proposed Dividend: EUR2.20 per share. Full Year 2024 Net Sales: EUR21.16 billion. Full Year 2024 EBITDA Pre: EUR6.07 billion. Full Year 2024 EPS Pre: EUR8 ...